LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER Clinical Trials

21 clinical trials for LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A PHASE 2/3 OPEN LABEL RANDOMIZED STUDY OF TELISOTUZUMAB ADIZUTECAN COMPARED TO STANDARD OF CARE IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER AFTER PROGRESSION ON A THIRD-GENERATION EGFR TKI - ANDROMETA-LUNG-713 — RECRUITING · PHASE2
• A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIRMONERTINIB COMPARED WITH INVESTIGATOR’S CHOICE OF OSIMERTINIB OR AFATINIB AS FIRST-LINE TREATMENT IN PARTICIPANTS WHO HAVE LOCALLY ADVANCED OR METASTATIC NON-SMALLCELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR P-LOOP AND ALPHA C-HELIX COMPRESSING (PACC) UNCOMMON MUTATIONS (ALPACCA) — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON¿SMALL CELL LUNG CANCER — RECRUITING · PHASE3
• A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE STUDY OF DATOPOTAMAB DERUXTECAN OR DOCETAXEL IN PREVIOUSLY TREATED TROP2-POSITIVE ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG17) — RECRUITING · PHASE3
• A PHASE 1/2 OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF BH-30643 IN ADULT SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC HARBORING EGFR AND/OR HER2 MUTATIONS (SOLARA) — RECRUITING · PHASE1
• A PHASE III, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTRE, INTERNATIONAL STUDY OF DURVALUMAB PLUS DOMVANALIMAB (AB154) IN PARTICIPANTS WITH LOCALLY ADVANCED (STAGE III), UNRESECTABLE NON SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED FOLLOWING DEFINITIVE PLATINUM BASED CONCURRENT CHEMORADIATION THERAPY (PACIFIC 8) — RECRUITING · PHASE3
• A RANDOMIZED PHASE 3 STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) AND PEMBROLIZUMAB, WITH OR WITHOUT PLATINUM CHEMOTHERAPY, IN SUBJECTS WITH NO PRIOR THERAPY FOR ADVANCED OR METASTATIC PD-L1 TPS <50% NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG07) — RECRUITING · PHASE3
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE ZIMBERELIMAB AND DOMVANALIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH NO EPIDERMAL GROWTH FACTOR RECEPTOR OR ANAPLASTIC LYMPHOMA KINASE GENOMIC TUMOR ABERRATIONS — RECRUITING · PHASE3
• A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE, GLOBAL STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) IN COMBINATION WITH DURVALUMAB AND CARBOPLATIN VERSUS PEMBROLIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS (AVANZAR) — RECRUITING · PHASE3
• A PHASE III, RANDOMISED, OPEN-LABEL STUDY OF SAVOLITINIB IN COMBINATION WITH OSIMERTINIB VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH EGFR MUTATED MET OVEREXPRESSED AND/OR AMPLIFIED, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON TREATMENT WITH OSIMERTINIB (SAFFRON) — RECRUITING · PHASE3
• AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TRASTUZUMAB DERUXTECAN AS FIRST-LINE TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC NSCLC HARBORING HER2 EXON 19 OR 20 MUTATIONS (DESTINY LUNG04) — RECRUITING · PHASE3
• A PHASE 3 STUDY OF PEMBROLIZUMAB IN COMBINATION WITH PEMETREXED/PLATINUM (CARBOPLATIN OR CISPLATIN) FOLLOWED BY PEMBROLIZUMAB AND MAINTENANCE OLAPARIB VS MAINTENANCE PEMETREXED IN THE FIRST-LINE TREATMENT OF PARTICIPANTS WITH METASTATIC NONSQUAMOUS NON-SMALL-CELL LUNG CANCER — RECRUITING · PHASE3
• A PHASE II, OPEN LABEL, SINGLE-ARM, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OSIMERTINIB WITH AMIVANTAMAB AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (OSTARA) — NOT_YET_RECRUITING · PHASE2
• SHORT PRE-SURGICAL PLAN IN LOCALLY ADVANCE NON-SMALL CELL LUNG CANCER EMPLOYING RADIATION, IMMUNO-ONCOLOGY AND RESECTION (SUPERIOR TRIAL) — NOT_YET_RECRUITING
• PHASE 1 FIRST-IN-HUMAN STUDY TO EXPLORE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF AMG 794 IN SUBJECTS WITH CLAUDIN 6 POSITIVE ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER, EPITHELIAL OVARIAN CANCER, AND OTHER MALIGNANT SOLID TUMOR INDICATIONS — NOT_YET_RECRUITING · PHASE1
• A PHASE II, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, CONTROLLED STUDY OF RO7247669 PLUS PLATINUM-BASED CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC NON - SMALL CELL LUNG CANCER — COMPLETED · PHASE2
• A DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CAPMATINIB (INC280) AND SPARTALIZUMAB (PDR001) COMBINATION THERAPY VERSUS CAPMATINIB AND PLACEBO AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WITH MET EXON 14 SKIPPING MUTATIONS — COMPLETED · PHASE2
• A RANDOMIZED, OPEN LABEL, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CAPMATINIB (INC280) PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH PD-L1¿ 50% — COMPLETED · PHASE2
• A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 2 TRIAL COMPARING VELIPARIB PLUS CARBOPLATIN AND PACLITAXEL VERSUS INVESTIGATOR'S CHOICE OF STANDARD CHEMOTHERAPY IN SUBJECTS RECEIVING FIRST CYTOTOXIC CHEMOTHERAPY FOR METASTATIC OR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) AND WHO ARE CURRENT OR FORMER SMOKERS. — COMPLETED · PHASE2
• A PHASE II STUDY TO INVESTIGATE A COMBINATION OF METFORMIN WITH CHEMO-RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER. — COMPLETED · PHASE2
• A PHASE II, OPEN LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF AZD9291 IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER WHOSE DISEASE HAS PROGRESSED WITH PREVIOUS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR THERAPY AND WHOSE TUMOURS ARE EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION AND T790M MUTATION POSITIVE (AURA2) — COMPLETED · PHASE2

Refine this search